Is Fusithalmic (fusidic acid) eyedrop safe for a baby under 2 years old?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 24, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Fusidic Acid (Fucithalmic) Eye Drops in Infants Under 2 Years

Fusidic acid 1% viscous eye drops (Fucithalmic) is safe and effective for treating bacterial conjunctivitis in babies under 2 years of age, including neonates, with twice-daily dosing providing excellent compliance and clinical outcomes.

Evidence for Safety and Efficacy in Young Infants

The evidence strongly supports the use of fusidic acid eye drops in very young children:

  • A large randomized controlled trial specifically evaluated 456 neonates (gestational age >32 weeks) with acute bacterial conjunctivitis in the first 28 days of life, demonstrating 89% cure rates with fusidic acid 1% applied twice daily, with no safety concerns reported 1

  • Compliance was significantly superior with fusidic acid compared to chloramphenicol (90.7% vs 78.0%, p<0.001) in neonates, primarily due to the convenient twice-daily dosing regimen 1

  • In children aged 2-9 years with bacterial conjunctivitis, fusidic acid showed significantly better compliance (85% vs 47%, p<0.001) and was rated as more convenient (97% vs 54%, p<0.001) compared to tobramycin 2

Pharmacokinetic Advantages

Fusidic acid viscous eye drops have unique sustained-release properties that make them particularly suitable for pediatric use:

  • The carbomer vehicle provides prolonged antibiotic concentrations in tear fluid with an excretion half-life of 1.9 hours, allowing effective twice-daily dosing 3

  • Adequate intraocular penetration is achieved, with aqueous humor levels of 0.3-0.8 mcg/ml maintained for at least 12 hours after dosing 4

Clinical Efficacy

  • Clinical and bacteriologic efficacy of fusidic acid is equivalent to other broad-spectrum antibiotics like tobramycin, with 65.9% of suspected bacterial conjunctivitis cases showing positive bacterial cultures 2

  • The presence of mucopurulent discharge directly correlates with bacterial pathogens, making fusidic acid an appropriate first-line choice for suspected bacterial conjunctivitis 2

Dosing Recommendation

For infants under 2 years with suspected bacterial conjunctivitis: Apply one drop of fusidic acid 1% to the affected eye(s) twice daily for 7 days 2, 1

Important Caveats

  • The neonatal study specifically included infants with gestational age >32 weeks, so use caution in extremely premature infants 1

  • While the evidence documents safety in neonates and young children, always monitor for any adverse reactions, though none were reported in the clinical trials 2, 1

  • The twice-daily dosing significantly improves compliance compared to more frequent dosing regimens required by other antibiotics, which is particularly important in young children 1

References

Research

Treatment of acute bacterial conjunctivitis: 1% fusidic acid viscous drops vs. 0.3% tobramycin drops.

Canadian journal of ophthalmology. Journal canadien d'ophtalmologie, 2002

Research

Fusidic acid in tear fluid: pharmacokinetic study with fusidic acid viscous eye drops.

European journal of drug metabolism and pharmacokinetics, 1987

Research

Intraocular penetration of fusidic acid with topical Fucithalmic.

European journal of drug metabolism and pharmacokinetics, 1985

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.